Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond

Nature Reviews Drug Discovery

Volumn 5, Issue 2, 2006, Pages 160-170

  Lipton, Stuart A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; DIZOCILPINE; DONEPEZIL; FREE RADICAL; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NITROMEMANTINE; NOOTROPIC AGENT; PHENCYCLIDINE; UNCLASSIFIED DRUG; AMINO ACID RECEPTOR BLOCKING AGENT; DRUG DERIVATIVE; NEUROPROTECTIVE AGENT; NEUROTOXIN;

AGITATION; AKATHISIA; ALZHEIMER DISEASE; CALCIUM TRANSPORT; CLINICAL TRIAL; COMA; COVALENT BOND; DEMENTIA; DEPRESSION; DIABETIC NEUROPATHY; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG APPROVAL; DRUG BINDING SITE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EUROPEAN UNION; EXCITOTOXICITY; FOOD AND DRUG ADMINISTRATION; GLAUCOMA; HALLUCINATION; HUMAN; MOLECULAR MECHANICS; MULTIINFARCT DEMENTIA; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; RESTLESSNESS; REVIEW; STRUCTURE ACTIVITY RELATION; SYSTEMATIC REVIEW; UNITED STATES; ANIMAL; DRUG ANTAGONISM;

ANIMALS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MEMANTINE; NEUROPROTECTIVE AGENTS; NEUROTOXINS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 33645095476     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd1958     Document Type: Review

References (100)

1. Lipton, S. A. & Rosenberg, P. A. Mechanisms of disease: Excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J. Med. 330, 613-622 (1994).
2. Lipton, S. A. & Nicotera, P. Calcium, free radicals and excitotoxins in neuronal apoptosis. Cell Calcium 23, 165-171 (1998).
3. Choi, D. W. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1, 623-634 (1988).
4. Meldrum, B. & Garthwaite, J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol. Sci. 11, 379-387 (1990).
5. Rothman, S. M. & Olney, J. W. Excitotoxicity and the NMDA receptor. Trends Neurosci. 10, 299-302 (1987).
6. 2+ block of the N-methyl-D-aspartate receptor underlies receptor activation during inhibition of neuronal metabolism. J. Neurochem. 59, 1211-1220 (1992).
7. Hardingham, G. E., Fukunaga, Y. & Bading, H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nature Neurosci. 5, 405-414 (2002).
8. Kemp, J. A. & McKernan, R. M. NMDA receptor pathways as drug targets. Nat. Neurosci. 5 (Suppl.), 1039-1042 (2002).
9. Lees, K. R. et al. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: A randomised controlled trial. GAIN International Investigators. Lancet 355, 1949-1954 (2000).
10. Sacco, R. L. et al. Glycine antagonist in neuroprotection for patients with acutA stroke: GAIN Americas: a randomized controlled trial. JAMA 285, 1719-1728 (2001).
11. Kemp, J. A., Kew, J. N. & Gill, D. L. in Handbook of Experimental Pharmacology (eds. Jonas, P. & Monyer, H.) 495-527 (Springer, Berlin, 1999).
12. Seif el Nasr, M., Perucher, B., Rossberg, C., Mennel, H.-D. & Krieglstein, J. Neuroprotective effect of memantine demonstrated in vivo and in vitro. Eur. J Pharmacol. 185, 19-24 (1990).
13. Lipton, S. A. Prospects for clinically tolerated NMDA antagonists: open-channel blockers and alternative redox states of nitric oxide. Trends Neurosci 16, 527-532 (1993).
14. Chen, H.-S. V. & Lipton, S. A. Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: Uncompetitive antagonism. J. Physiol. (Land.) 499, 27-46 (1997).
15. Chen, H.-S. V. et al. Open-channel block of NMDA responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J. Neurosci. 12, 4427-4436 (1992).
16. Chen, H.-S. V. et al. Neuroprotective concentrations of the NMDA open-channel blacker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or LTP. Neuroscience 86, 1121-1132 (1998).
17. Reisberg, B. et al. Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 348, 1333-1341 (2003).
18. Orgogozo, J. M., Rigaud, A. S., Stoffler, A., Mobius, H. J. & Forette, F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: A randomized, placebo-controlled trial (MMM 300). Stroke 33, 1834-1839 (2002).
19. Lucas, D. R. & Newhouse, J. P. The toxic effect of sodium L-glutamate on the inner layers of the retina. Arch. Ophothalmol. 58, 193-201 (1957).
20. Olney, J. W. Glutamate-induced retinal degeneration in neonatal mice. Electron microscopy of the acutely evolving lesion. J. Neuropathol. Exp. Neurol. 28, 455-474 (1969).
21. Olney, J. W. & Ho, O. L. Brain damage in infant mice following oral intake of glutamate, aspartate or cysteine. Nature 227, 609-611 (1970).
22. Lipton, S. A. Molecular mechanisms of trauma-induced neuronal degeneration. Curr. Opin. Neurol. Neurosurg. 6, 588-596 (1993).
23. Ankarcrona, M. et al. Glutamate-induced neuronal death: A succession of necrosis or apoptosis depending on mitochondrial function. Neuron 15, 961-973 (1995).
24. Bonfoco, E., Krainc, D., Ankarcrona, M., Nicotera, P. & Lipton, S. A. Apoptosis and necrosis: Two distinct events induced respectively by mild and intense insults with NMDA or nitric oxide/superoxide in cortical cell cultures. Proc. Natl. Acad. Sci. USA 92, 7162-7166 (1995).
25. Dreyer, E. B., Zhang, D. & Lipton, S. A. Transciptional or translational inhibition blocks low dose NMDA-mediated cell death. NeuroReport 6, 942-944 (1995).
26. Quigley, H. A. et al. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest. Ophthalmol. Vis. Sci. 36, 774-786 (1995).
27. Vorwerk, C. K. et al. Chronic low dose glutamate is toxic to retinal ganglion cells: Toxicity blocked by memantine. Invest. Ophthalmol. Vis. Sci. 37, 1618-1624 (1996).
28. Dreyer, E. B. & Grosskreutz, C. L. Excitatory mechanisms in retinal ganglion cell death in primary open angle glaucoma (POAG). Clin. Neurosci. 4, 270-273 (1997).
29. Dreyer, E. B. & Lipton, S. A. New perspectives on glaucoma. JAMA 281, 306-308 (1999).
30. Naskar, R., Vorwerk, C. K. & Dreyer, E. B. Saving the nerve from glaucoma: Memantine to caspaces. Semin. Ophthalmol. 14, 152-158 (1999).
31. Berliocchi, L. et al. Botulinum neurotoxin C initiates two different programs for neurite degeneration and neuronal apoptosis. J. Cell Biol. 168, 607-618 (2005).
32. Garden, G. A. et al. Caspase cascades in human immunodeficiency virus-associated neuro-degeneration. J. Neurosci. 22, 4015-4024 (2002).
33. Dawson, V. L., Dawson, T. M., London, E. D., Bredt, D. S. & Snyder, S. H. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc. Natl Acad. Sci. USA 88, 6368-6371 (1991).
34. Dawson, V. L., Dawson, T. M., Bartley, D. A., Uhl, G. R. & Snyder, S. H. Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures. J. Neurosci. 13, 2651-2661 (1993).
35. Lipton, S. A. et al. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature 364, 626-632 (1993).
36. Tenneti, L., D'Emilia, D. M., Troy, C. M. & Lipton, S. A. Role of caspases in N-methyl-D-aspartate-induced apoptosis of cerebrocortical neurons. J. Neurochem. 71, 946-959 (1998).
37. ras. Proc. Natl Acad. Sci. USA 95, 5773-5778 (1998).
38. Budd, S. L., Tenneti, L., Lishnak, T. & Lipton, S. A. Mitochondrial and extramitochondrial apoptotic signaling pathways in cerebrocortical neurons. Proc. Natl Acad. Sci. USA 97, 6161-6166 (2000).
39. Okamoto, S. et al. Dominant-interfering forms of MEF2 generated by caspase cleavage contribute to NMDA-induced neuronal apoptosis. Proc. Natl Acad. Sci. USA 99, 3974-3979 (2002).
40. Wang, H. et al. Apoptosis-inducing factor substitutes for caspase executioners in NMDA-triggered excitotoxic neuronal death. J. Neurosci. 24, 10963-10973 (2004).
41. Hara, M. R. et al. S-nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah 1 binding. Nature Cell. Biol. 7, 665-674 (2005).
42. Johnson, J. W. & Ascher, P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 325, 529-531 (1987).
43. Shleper, M., Kartvelishvily, E. & Wolosker, H. D-serine is the dominant endogenous coagonist for NMDA receptor neurotoxicity in organotypic hippocampal slices. J. Neurosci. 25, 9413-9417 (2005).
44. Mothet, J. P. et al. D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. Proc. Natl Acad. Sci. USA 97, 4926-4931 (2000).
45. Wolosker, H., Blackshaw, S. & Snyder, S. H. Serine racemase: A glial enzyme synthesizing D-serine to regulate glutamate-N-methyl-D-aspartate neurotransmission. Proc. Natl Acad. Sci. USA 96, 13409-13414 (1999).
46. McBain, C. J. & Mayer, M. L. N-Methyl-D-aspartic acid receptor structure and function. Physiol. Rev. 74, 723-760 (1994).
47. Lipton, S. A. et al. Cysteine regulation of protein function - as exemplified by NMDA-receptor modulation. Trends Neurosci. 25, 474-480 (2002).
48. Koroshetz, W. J. & Moskowitz, M. A. Emerging treatments for stroke in humans. Trends Pharmacol. Sci. 17, 227-233 (1996).
49. Hickenbottom, S. L. & Grotta, J. Neuroprotective therapy. Semin. Neurol. 18, 485-492 (1998).
50. Lutsep, H. L. & Clark, W. M. Neuroprotection in acute ischaemic stroke. Current status and future potential. Drugs R 6r D 1, 3-8 (1999).
51. Rogawski, M. A. Low affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents - toward an understanding of their favorable tolerability. Amino Acids 19, 133-149 (2000).
52. Palmer, G. C. Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies. Curr. Drug Targets 2, 241-271 (2001).
53. Chen, H.-S. V. & Lipton, S. A. Pharmacological implications of two distinct mechanisms of interaction of memantine with NMDA-gated channels. J. Pharmacol. Exp. Ther. 314, 961-971 (2005).
54. Bormann, J. Memantine is a potent blacker of N-methyl-D-aspartate (NMDA) receptor channels. Eur. J. Pharmacol. 166, 591-592 (1989).
55. Bresink, I. et al. Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells. Br. J. Pharmacol 119, 195-204 (1996).
56. Chen, H.-S. V. & Lipton, S. A. in Post Genomic Drug Discovery Research (ed. Huang, Z.) (John Wiley & Sons, Hoboken, NJ (in the press).
57. Blanpied, T. A., Boekman, F. A., Aizenman, E. & Johnson, J. W. Trapping channel block of NMDA-activated responses by amantadine and memantine. J. Neurophysiol. 77, 309-323 (1997).
58. Blanpied, T. A., Clarke, R. J. & Johnson, J. W. Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J. Neurosci. 25, 3312-3322 (2005).
59. Sobolevsky, A. I., Koshelev, S. G. & Khodorov, B. I. Interaction of memantine and amantadine with agonist-unbound NMDA-receptor channels in acutely isolated rat hippocampal neurons. J. Physiol. (Lond.) 512, 47-60 (1998).
60. Rammes, G., Rupprecht, R., Ferrari, U., Zieglgansberger, W. & Parsons, C. G. The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N 1 E-115 cell systems in a non-competitive manner. Neurosci. Lett. 306, 81-84 (2001).
61. Reiser, G., Binmoller, F. J. & Koch, R. Memantine (1-amino-3,5-dimethyladamantane) blocks the serotonin-induced depolarization response in a neuronal cell line. Brain Res. 443, 338-344 (1988).
62. Parsons, C. G., Danysz, W. & Quack, G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology 38, 735-767 (1999).
63. Lipton, S. A. Memantine prevents HIV coat protein-induced neuronal injury in vitro. Neurology 42, 1403-1405 (1992).
64. Pellegrini, J. W. & Lipton, S. A. Delayed administration of memantine prevents N-methyl-D-aspartate receptor-mediated neurotoxicity Ann. Neurol. 33, 403-407 (1993).
65. Sucher, N. J., Lipton, S. A. & Dreyer, E. B. Molecular basis of glutamate toxicity in retinal ganglion cells. Vision Res. 37, 3483-3493 (1997).
66. Osborne, N. N. Memantine reduces alterations to the mammalian retina, in situ, induced by ischemia. Vis. Neurosci. 16, 45-52 (1999).
67. Navia, B. A., Yiannoutsos, C., Ellis, R., Schifitto, G., Nath, A., Shriver, S., Millar, L. & Lipton, S. A. Memantine may prevent further cognitive decline in subjects with AIDS Dementia Complex with detectable CSF HIV RNA. Neurology 64 (Suppl. 1), A247-A238 (2005).
68. Tariot, P. N. et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. JAMA 291, 317-324 (2004).
69. 9M-best study (benefit and efficacy in severely demented patients during treatment with memantine). Int. J. Geriat. Psych. 14, 135-146 (1999).
70. Lipton, S. A. & Wang, Y. F. in Pharmacology of Cerebral Ischemia (ed. Krieglstein, J.) 183-191 (Medpharm Scientific, Stuttgart, 1996).
71. Zurakowski, D. et al. Nitrate therapy may retard glaucomatous optic neuropathy, perhaps through modulation of glutamate receptors. Vision Res. 38, 1489-1494 (1998).
72. Lipton, S. A., Rayudu, P. V., Choi, Y.-B., Sucher, N. J. & Chen, H. S. V. in Prog Brain Res. (eds Mize, V., Dawson, T. M., Dawson, M. & Friedlander, M.) 73-82 (Elsevier, Amsterdam, 1998).
73. Choi, Y.-B. et al. Molecular basis of NMDA receptor-coupled ion channel modulation by S-nitrosylation. Nature Neurosci. 3, 15-21 (2000).
74. Le, D. A. & Lipton, S. A. Potential and current use of N-methyl-D-aspartate (NMDA) receptor antagonists in diseases of aging. Drugs Aging 18, 717-724 (2001).
75. Lipton, S. A. Concepts: Turning down, but not off. Nature 428, 473 (2004).
76. Lipton, S. A. & Chen, H. S. Paradigm shift in neuroprotective drug development: Clinically tolerated NMDA receptor inhibition by memantine. Cell Death Differ. 11, 18-20 (2004).
77. Salter, M. & Fern, R. NMDA receptors are expressed in developing oligodendrocyte processes and mediate injury. Nature (in the press).
78. Káradóttir, R., Cavelier, P., Bergersen, L. H. & Atwell, D. NMDA receptors in oligodendrocyte physiology and pathology. Nature (in the press).
79. Micu, I. et al. NMDA receptors mediate Ca accumulation in central nervous system myelin during chemical ischemia. Nature (in the press).
80. Stern-Bach, Y., Bettler, B., Hartley, M., Sheppard, P. O., O'Hara, P. J. & Heinemann, S. F. Agonist selectivity of glutamate receptors is specified by two domains structurally related to bacterial amino acid-binding proteins. Neuron 13, 1345-1357 (1994).
81. Monyer, H. et al. Heteromeric NMDA receptors: Molecular and functional distinction of subtypes. Science 256, 1217-1221 (1992).
82. Nakanishi, S. Molecular diversity of glutamate receptors and implications for brain function. Science 258, 597-603 (1992).
83. Meguro, H. et al. Functional characterization of a heteromeric NMDA receptor channel expressed from cloned cDNAs. Nature 357, 70-74 (1992).
84. Kleckner, N. W. & Dingledine, R. Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science 241, 835-837 (1988).
85. 2+ of NMDA responses in spinal cord neurones. Nature 309, 261-263 (1984).
86. Nowak, L., Bregestovski, P., Ascher, P., Herbet, A. & Prochiantz, A. Magnesium gates glutamate-activated channels in mouse central neurones. Nature 307, 462-465 (1984).
87. 2+-block site of the NMDA receptor channel. Nature 358, 673-675 (1992).
88. Huettner, J. E. & Bean, B. P. Block of N-methyl-D-aspartate-activated current by the anticonvulsant MK-801: Selective binding to open channels. Proc. Natl Acad. Sci. USA 85, 1307-1311 (1988).
89. Karschin, A., Aizenman, E. & Lipton, S. A. The interaction of agonists and noncompetitive antagonists at the excitatory amino acid receptors in rat retinal ganglion cells in vitro. J. Neurosci. 8, 2895-2906 (1988).
90. Rogawski, M. A. & Wenk, G. L. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev. 9, 275-308 (2003).
91. Selkoe, D. J. Alzheimer's disease: Genes, proteins, and therapy. Physiol. Rev. 81, 741-766 (2001).
92. 3H)purine release from rat brain cortical synaptosomes. Neurochem. Res. 9, 1019-1031 (1984).
93. Mattson, M. P. et al. νb-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity J. Neurosci. 12, 376-389 (1992).
94. Koh, J. Y., Yang, L. L. & Cotman, C. W. β-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res 533, 315-320 (1990).
95. Topper, R. et al. Rapid appearance of β-amyloid precursor protein immunoreactivity in glial cells following excitotoxic brain injury. Acta Neuropathol. (Berl.) 89, 23-28 (1995).
96. Harkany, T. et al. β-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. Eur. J. Neurosci. 12, 2735-2745 (2000).
97. Couratier, P. et al. Modifications of neuronal phosphorylated tau immunoreactivity induced by NMDA toxicity. Mol. Chem. Neuropathol. 27, 259-273 (1996).
98. Miguel-Hidalgo, J. J., Alvarez, X. A., Cacabelos, R. & Quack, G. Neuroprotection by memantine against neurodegeneration induced by βa-amyloid(1-40). Brain Res. 958, 210-221 (2002).
99. Minkeviciene, R., Banerjee, P. & Tanila, H. Memantine improves spatial learning in a transgenic mouse model of Alzheimer's disease. J. Pharmacol. Exp. Ther. 311, 677-682 (2004).
100. Li, L., Sengupta, A, Haque, N., Grundke-Iqbal, I. & Iqbal, K. Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett. 566, 261-269 (2004).